Actualizado 17/11/2006 02:03
- Comunicado -

Women With Early Breast Cancer are More Likely to Remain Cancer Free by Changing Treatment From Tamoxifen to Arimidex(TM

AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services. It is one of the world's leading pharmaceutical companies with healthcare sales of $23.95 billion and leading positions in sales of gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infection products. AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as well as the FTSE4Good Index.

For more information, please visit www.astrazenecapressoffice.com

For further information, please contact: Lynn Grant - AstraZeneca, Global PR Director - Oncology, Direct Line: +44-(0)-1625-517-406. Email: Lynn.Grant@Astrazeneca.com. Elly Brookes - Shire Health International, Direct Line: +44 (0) 20-7108-6533, Email: elly.brookes@shirehealthinternational.com

Contenido patrocinado